Abstract: Provided herein are devices for concurrent intravenous infusion of multiple drugs. The device comprises a body with a syringe holding portion and a syringe driving portion, two or more syringes secured therein and a multi-lumen catheter with a plurality of inlet channels and a single outlet channel. Also provided is a method for treating acute myocardial infarction complicated by advanced acute heart failure in a patient. Two or more drugs, such as a beta-blocker and a positive inotropic agent, in prefilled syringes are secured in the device and administered simultaneously into a single vein in a patient without the drugs mixing prior to administration. In addition, a kit is provided that comprises the device and syringes prefilled with a beta-blocker and the positive inotropic agent.

Abstract: Provided herein are devices for concurrent intravenous infusion of multiple drugs. The device comprises a body with a syringe holding portion and a syringe driving portion, two or more syringes secured therein and a multi-lumen catheter with a plurality of inlet channels and a single outlet channel. Also provided is a method for treating acute myocardial infarction complicated by advanced acute heart failure in a patient. Two or more drugs, such as a beta-blocker and a positive inotropic agent, in prefilled syringes are secured in the device and administered simultaneously into a single vein in a patient without the drugs mixing prior to administration. In addition, a kit is provided that comprises the device and syringes prefilled with a beta-blocker and the positive inotropic agent.

Abstract: The present invention discloses methods to prevent and treat cardiovascular disorders, hi certain aspects the methods are drawn to releasing endogenous calcitonin-gene related peptide from intrinsic cardiac adrenergic cells within the heart. In further aspects, a combination of a ?2 adrenergic receptor agonist (?2-AR agonist) and a vasodilator can be used in treating reperfusion injury.

Abstract: Embodiments of the invention are directed to methods of treating reperfusion or resuscitation injury in an individual in need of such treatment, comprising the step of administering to the individual who has had, having, or is at immediate risk of having an ischemic event an amount of a composition comprising a protein kinase A (PKA) activator and a ?1-adrenergic receptor antagonist sufficient to reduce reperfusion injury to an ischemic tissue.

Abstract: Embodiments of the invention are directed to methods of treating reperfusion or resuscitation injury in an individual in need of such treatment, comprising the step of administering to the individual who has had, having, or is at immediate risk of having an ischemic event an amount of a composition comprising a protein kinase A (PKA) activator and a ?1-adrenergic receptor antagonist sufficient to reduce reperfusion injury to an ischemic tissue.

Abstract: The present invention discloses methods to prevent and treat cardiovascular disorders, hi certain aspects the methods are drawn to releasing endogenous calcitonin-gene related peptide from intrinsic cardiac adrenergic cells within the heart. In further aspects, a combination of a ?2 adrenergic receptor agonist ?2-AR agonist) and a vasodilator can be used in treating reperfusion injury.

Abstract: The present invention describes methods for treating heart diseases by pharmacological manipulation of intrinsic cardiac adrenergic cells. The activation or inhibition of ?-opioid receptors or selective ?2-adrenergic receptor agonist in these cells can help regulate catecholamine synthesis and release in these cells. Thus drugs directed towards these receptors can be used in the treatment of heart diseases including acute and chronic congestive heart failure, as well as acute and chronic coronary artery disease. The present invention also describes a method of treating acute decompensated congestive heart failure using ?-opioid receptor agonists or selective ?2-adrenergic receptor agonists to stimulate endogenous production of brain natriuretic peptide.